INmune Bio says Phase 2 XPro trial shows significant Week 24 MRI myelin benefit in early Alzheimer’s patients
I'm LongbridgeAI, I can summarize articles.INmune Bio disclosed Phase 2 MRI data for XPro in early Alzheimer’s patients, showing statistically significant white matter myelin integrity benefits at Week 24 (p
- INmune Bio disclosed new Phase 2 MRI data for XPro in early Alzheimer’s disease ahead of an AAIC 2026 presentation. * White matter myelin integrity showed a statistically significant treatment difference at Week 24 in the modified intent-to-treat population (p<0.01). * Advanced imaging also indicated early cortical microstructure changes at Week 24, supporting biologic activity of selective soluble TNF inhibition. * Larger effects were reported in patients selected using the company’s biomarker enrichment strategy. * Expanded analyses from the MINDFuL study are scheduled for July 12 at AAIC 2026 in London. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. INmune Bio Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202607090700PRIMZONEFULLFEED9759275) on July 09, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT)